Industry Outlook 1999/ Pharmaceuticals
Although times are heady for the pharmaceutical industry, Morgan Stanley Dean Witter analyst Paul Brooke doesn't think the boom will continue. Industry growth will be stymied by genericization and the introduction of fewer big new products. At the same time, the industry faces restraints on its pricing flexibility, one of the keys to its recent success.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.